During the last three months, 7 analysts shared their evaluations of Paragon 28 (NYSE:FNA), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $16.57, along with a high estimate of $18.00 and a low estimate of $14.00. This current average has decreased by 2.53% from the previous average price target of $17.00.
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Paragon 28 is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt O'Brien | Piper Sandler | Lowers | Overweight | $15.00 | $18.00 |
| Mike Matson | Needham | Lowers | Buy | $14.00 | $17.00 |
| George Sellers | Stephens & Co. | Maintains | Overweight | $18.00 | - |
| Mike Matson | Needham | Maintains | Buy | $17.00 | - |
| Mike Matson | Needham | Maintains | Buy | $17.00 | - |
| Matt O'Brien | Piper Sandler | Maintains | Overweight | $18.00 | - |
| Mike Matson | Needham | Raises | Buy | $17.00 | $16.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Paragon 28. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paragon 28 compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Paragon 28's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Paragon 28's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Paragon 28 analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Paragon 28's Background
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
Paragon 28: Financial Performance Dissected
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Paragon 28's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.58% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Paragon 28's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -32.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Paragon 28's ROE excels beyond industry benchmarks, reaching -10.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Paragon 28's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.17%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Paragon 28's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.